{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:59:31Z","timestamp":1787979571935,"version":"build-2784847793"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T00:00:00Z","timestamp":1478908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["N00014\u201015\u20101\u20100848"],"award-info":[{"award-number":["N00014\u201015\u20101\u20100848"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["N00014\u201016\u20101\u20102020"],"award-info":[{"award-number":["N00014\u201016\u20101\u20102020"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>Older adults with B\u2010cell acute lymphoblastic leukemia (B\u2010ALL) have poor survival. We examined the effectiveness of reduced intensity conditioning (RIC) hematopoietic cell transplant (HCT) in adults with B\u2010ALL age 55 years and older and explored prognostic factors associated with long\u2010term outcomes. Using CIBMTR registry data, we evaluated 273 patients (median age 61, range 55\u201372) with B\u2010ALL with disease status in CR1 (71%), &gt;CR2 (17%) and Primary Induction Failure (PIF)\/Relapse (11%), who underwent RIC HCT between 2001 and 2012 using mostly unrelated donor (59%) or HLA\u2010matched sibling (32%). Among patients with available cytogenetic data, the Philadelphia chromosome (Ph+) was present in 50%. The 3\u2010year cumulative incidences of nonrelapse mortality (NRM) and relapse were 25% (95% confidence intervals (CI): 20\u201331%) and 47% (95% CI: 41\u201353%), respectively. Three\u2010year overall survival (OS) was 38% (95% CI: 33\u201344%). Relapse remained the leading cause of death accounting for 49% of all deaths. In univariate analysis, 3 year risk of NRM was significantly higher with reduced Karnofsky performance status (KPS &lt;90: 34% (95% CI: 25\u201343%) versus KPS \u226590 (18%; 95% CI: 12\u201324%, <jats:italic>P<\/jats:italic>\u2009=\u20090.006). Mortality was increased in older adults (66+ vs. 55\u201360: Relative Risk [RR] 1.51 95% CI: 1.00\u20132.29, <jats:italic>P<\/jats:italic>\u2009=\u20090.05) and those with advanced disease (RR 2.13; 95% CI: 1.36\u20133.34, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). Survival of patients in CR1 yields 45% (95% CI: 38\u201352%) at 3 years and no relapse occurred after 2 years. We report promising OS and acceptable NRM using RIC HCT in older patients with B\u2010ALL. Disease status in CR1 and good performance status are associated with improved outcomes.  Am. J. Hematol. 92:42\u201349, 2017. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24575","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T01:08:10Z","timestamp":1476320890000},"page":"42-49","source":"Crossref","is-referenced-by-count":49,"title":["Reduced intensity conditioned allograft yields favorable survival for older adults with B\u2010cell acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"92","author":[{"given":"Ashley E.","family":"Rosko","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine Ohio State University Columbus Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai\u2010Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin CIBMTR, Center for International Blood and Marrow Transplant Research Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[{"name":"Department of Medicine, Seidman Cancer Center University Hospitals Case Medical Center Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Jean","family":"Khoury","sequence":"additional","affiliation":[{"name":"Emory University Hospital Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology University of Chicago School of Medicine Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan","family":"Brammer","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bredeson","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Farag","sequence":"additional","affiliation":[{"name":"Indiana University Hospital\/Riley Hospital for Children Indianapolis Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Kharfan\u2010Dabaja","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation H. Lee Moffit Cancer Center and Research Institute Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Seidman Cancer Center University Hospitals Case Medical Center Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant University Hospitals Bristol NHS Trust Bristol United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Martino Bufarull","sequence":"additional","affiliation":[{"name":"Division of Clinical Hematology Hospital de la Santa Creu I Sant Pau Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[{"name":"University of Kansas Westwood Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Mohty","sequence":"additional","affiliation":[{"name":"Hopital Saint\u2010Antoine APHP, Universite Pierre &amp; Marie Curie, INSERM UMRs U938 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation H. Lee Moffit Cancer Center and Research Institute Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Nivison\u2010Smith","sequence":"additional","affiliation":[{"name":"St. Vincent's Hospital Darlinghurst New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Rashidi","sequence":"additional","affiliation":[{"name":"Barnes Jewish Hospital St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Ringden","sequence":"additional","affiliation":[{"name":"Division of Therapeutic Immunology, Department of Laboratory Medicine Karolinska Institutet Stockholm Sweden"},{"name":"Centre for Allogeneic Stem Cell Transplantation Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Seftel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"Divsion of Hematology, Oncology and Transplantation, Department of Medicine University of Minnesota Medical Center Minneapolis Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"Bone and Marrow Transplant Program University of Minnesota Medical Center Minneapolis Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin CIBMTR, Center for International Blood and Marrow Transplant Research Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1623"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164863"},{"key":"e_1_2_7_4_1","article-title":"Fludarabine, Melphalan and Alemtuzumab conditioned reduced intensity (RIC) allogeneic hematopoietic cell transplantation for adults aged >40 years with de novo acute lymphoblastic leukemia: A prospective study from the UKALL14 trial (ISRCTN 66541317)[abstract]","volume":"126","author":"Okasha DKA","year":"2015","journal-title":"Blood"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232124"},{"key":"e_1_2_7_6_1","unstructured":"SurveillanceE.End Results (SEER) Program Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program National Cancer Institute. Available athttp:\/\/seer.cancer.gov\/faststats. [Accessed 10.13.2016]"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412123"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529008"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1287"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3785"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.253"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2177"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4386"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404320"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-329003"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.217"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.2446"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.94"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.098"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.07.004"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.04.003"},{"key":"e_1_2_7_23_1","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90380-0"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-266551"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23465"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.140"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.12.497"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703355"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.03.004"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-234492"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1014365"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.11.006"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29717"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.8157"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0010"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8347"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-471680"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.6559"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0137"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7625"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-264077"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.117"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds655"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-599894"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_2_7_47_1","first-page":"337","article-title":"Efficacy and safety of Inotuzumab Ozogamicin (Ino) vs standard of care (Soc) in salvage 1 or 2 patients with acute lymphoblastic leukemia (All): An ongoing global phase 3 study","volume":"100","author":"DeAngelo DJ","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-580043"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.24575","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/chorus\/v1\/articles\/10.1002%2Fajh.24575","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T01:57:39Z","timestamp":1695002259000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1002\/ajh.24575"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24575","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,12]]}}}